<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0012115'>Hepatitis</z:hpo> B virus (HBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> is known to be responsible for both hepatic and extrahepatic manifestations including <z:hpo ids='HP_0000964'>dermatitis</z:hpo>, <z:e sem="disease" ids="C0162296" disease_type="Disease or Syndrome" abbrv="">polyarthralgias</z:e> and <z:hpo ids='HP_0001369'>arthritis</z:hpo>, <z:e sem="disease" ids="C0024115" disease_type="Disease or Syndrome" abbrv="">pulmonary disease</z:e>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0000099'>glomerulonephritis</z:hpo> and <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The mechanism of these extrahepatic disorders is thought to be linked to <z:e sem="disease" ids="C0020951" disease_type="Disease or Syndrome" abbrv="">immune complex disease</z:e>, but their pathogenesis is poorly clarified </plain></SENT>
<SENT sid="2" pm="."><plain>Immunosuppressive treatment could promote <z:mp ids='MP_0001799'>viral</z:mp> load and impair <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">hepatic disease</z:e>, also worsening the <z:hpo ids='HP_0002633'>vasculitis</z:hpo> by enhancing <z:mp ids='MP_0001799'>viral</z:mp> antigenemia </plain></SENT>
<SENT sid="3" pm="."><plain>Lamivudine is a <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogue approved for treating <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B, that decreases the amount of <z:mp ids='MP_0001799'>viral</z:mp> antigens by suppressing HBV replication </plain></SENT>
<SENT sid="4" pm="."><plain>Several reports have suggested lamivudine in the treatment of <z:hpo ids='HP_0002633'>vasculitis</z:hpo> associated with HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, but, although significant inhibition of HBV is achieved in the short term, resistance develops in 15-32 percent annual risk rating </plain></SENT>
<SENT sid="5" pm="."><plain>We report an elderly patient whose <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B decompensated <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> with associated refractory hepatic <z:mp ids='MP_0010334'>hydrothorax</z:mp> and extensive leukocytoclastic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> was successfully treated with ongoing long-term lamivudine monotherapy </plain></SENT>
</text></document>